Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

Johanna Mercier, Chief Commercial Officer of Gilead Sciences Inc (NASDAQ:GILD), sold 29,357 shares of the company on ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Gilead Sciences (GILD) and Genesis Therapeutics have entered into a strategic collaboration to discover and develop small molecule ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Malignant Pleural Mesothelioma.

For those with $200 to spare that isn't being saved for emergencies, let's consider two healthcare stocks within that budget ...

Gilead Sciences, Inc. and Genesis Therapeutics, Inc. have announced that the companies have entered into a strategic ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $81.44 which represents a slight increase of $2.27 or 2.87% from the prior close of $79.17. The stock opened at $79.17 and ...

Gilead Sciences and Genesis Therapeutics have entered a strategic collaboration to discover and develop novel small molecule ...

In a study of more than 3,000 participants, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.